

Elena Rodríguez-Sánchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4799357/publications.pdf>

Version: 2024-02-01

24
papers

241
citations

1163117

8
h-index

1058476

14
g-index

24
all docs

24
docs citations

24
times ranked

271
citing authors

#	ARTICLE	IF	CITATIONS
1	The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. <i>BMC Medicine</i> , 2022, 20, 14.	5.5	7
2	Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca ²⁺ mishandling and preventive role of Klotho in mice to its potential mortality prediction in human. <i>Translational Research</i> , 2022, 243, 60-77.	5.0	5
3	Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2266.	4.1	7
4	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. <i>Nefrologia</i> , 2022, 42, 519-530.	0.4	1
5	An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. <i>Frontiers in Physiology</i> , 2021, 12, 632260.	2.8	39
6	Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 602-617.	5.4	9
7	Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1198-1205.	3.6	4
8	Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 188-193.	3.0	18
9	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, , .	3.0	0
10	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca ²⁺ Alterations in Adult Ventricular Cardiomyocytes. <i>Antioxidants</i> , 2020, 9, 1213.	5.1	7
11	Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca ²⁺ handling. <i>British Journal of Pharmacology</i> , 2020, 177, 4701-4719.	5.4	24
12	Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. <i>Journal of Proteomics</i> , 2020, 222, 103816.	2.4	5
13	On the need of the simultaneous control of arterial hypertension and diabetes mellitus. <i>Journal of Clinical Hypertension</i> , 2020, 22, 221-222.	2.0	0
14	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. <i>Biomolecules</i> , 2020, 10, 505.	4.0	3
15	Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. <i>Transplantation</i> , 2020, 104, 2599-2608.	1.0	8
16	The endless story of markers of renal function and cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 3494-3495.	2.2	3
17	Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. <i>Translational Research</i> , 2019, 212, 54-66.	5.0	8
18	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019, 39, 184-191.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. <i>Nutrients</i> , 2019, 11, 2809.	4.1	13
20	Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1864-1875.	0.7	40
21	Asociación entre disminución de la función renal y actividad metaloproteinasa-9 en el paciente hipertenso. <i>Nefrología</i> , 2019, 39, 184-191.	0.4	8
22	Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. <i>Clinical Science</i> , 2018, 132, 739-758.	4.3	4
23	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. <i>Scientific Reports</i> , 2018, 8, 4802.	3.3	8
24	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9 Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017, 8, 853.	4.8	14